News
A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...
INDIANAPOLIS — A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback